Life Science Open Day | 2006 | Weizmann Institute of Science

972 8 947 0617

Yeda R&D Co. Ltd.

972 8 947 0739

info.yeda@weizmann.ac.il

Yeda Research and Development Company Ltd. functions as the commercial arm of the Weizmann Institute of Science. Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by Institute scientists.

Yeda holds an exclusive agreement with the Weizmann Institute to market and commercialize its intellectual property and generate income to support further research and education.

Yeda performs the following activities:

• Identifies and assesses research projects with commercial potential.

• Protects the intellectual property of the Institute and its scientists.

• Licenses the Institute’s inventions and technologies to industry.

• Channels funding from industry to research projects

Yeda Statistics for 2005

• Over 1000 presentations of Weizmann Technologies to companies.

• Over 100 presentations of confidential information to interested companies (under signed secrecy agreements).

• Over 20 new license and option agreements signed.

• Over 50 research projects at WIS were funded through Yeda by companies, by the chief scientist of the ministry of industry and trade and by Yeda itself.

Scientific Breakthroughs for the Public Benefit

Isaac Shariv

Einat Zisman

Amir Naiberg

Yaacov Cohen

Ruth Granoth

Ziv Hermon

Noa Shelach

http://yeda.weizmann.ac.il

Spanning the Natural Sciences

Weizmann Institute research and technologies cover a broad spectrum of the natural sciences, including:

• Life Sciences, Biotechnology and Bioinformatics

• Agriculture and Plant Genetics

• Chemistry and Materials

• Solar Energy and Environmental Sciences

• Physics and Electro-Optics

• Mathematics and Computer Science

Proven Commercial Success

Since its establishment in 1959, Yeda has entered into formal agreements with prominent investment groups and commercial enterprises, including several large multinational corporations.

Copaxone® The first innovative drug to be developed in Israel and to receive FDA approval, Copaxone® is a unique multiple sclerosis immunomodulator: the first and only non-interferon agent for the treatment of relapsing-remitting multiple sclerosis. Copaxone® is licensed to Teva Pharmaceuticals Ltd

Frone® (Native interferon beta), licensed to Inter-Lab Ltd., a Serono company, and used as an antiviral and anti-cancer drug, with sales exceeding 40$ million annually, until replaced by Rebif®.

Rebif® (Recombinant interferon beta), identical to the native molecule and registered for the treatment of multiple sclerosis and several viral diseases, licensed to Inter-Lab Ltd., a Serono company.

Dunaliella (Beta-carotene), a health food product with possible anti-cancer properties, extracted from Dunaliella, a local alga, licensed to Nikken Sohonsha Corporation

Encryption Algorithm This algorithm is licensed to NDS Ltd., and is widely used as the basis for television set-top box smart cards. To date, over 50 million smart cards are in use throughout the world.

GeneCards® A bioinformatics database, licensed to Xennex, Inc.

Vitamin Alpha D3® A molecule discovered by Institute researchers and produced under license by Teva Pharmaceuticals Ltd. for the treatment of osteoporosis and bone decalcification

Improved crop varieties and hybrid cultivars of cucumbers and melons are under license to Israeli seed companies.

Bio-Hep B® A recombinant hepatitis B vaccine that integrates the S, pre-S1, and pre-S2 surface proteins of the hepatitis B virus. Enables successful immunization with significantly lower doses of vaccine than other recombinant hepatitis B vaccines. Licensed to Bio-Technology General, Inc., a subsidiary of Ferring Inc. Bio-Hep-B is marketed in Israel and registrations in other countries are under way.

In the pipeline:

Diapep 277 Peptide vaccine for the treatment of type 1 diabetes, acts to protect the insulin producing beta-cells from auto immune destruction. DiaPep277® is licensed to Develogen (formerly Peptor Ltd.) and has successfully completed phase II clinical development. A pivotal phase III trial for the treatment of type 1 diabetes commenced in September 2005.

Hepex B® Combination of two fully human monoclonal antibodies against the hepatitis B virus surface antigen, HBsAg. It is being developed to prevent hepatitis B, known as HBV, re-infection following a liver transplant. Licensed to XTL Biopharmaceuticals Ltd. (XTLbio). HepeX-B is currently in a Phase IIb trial in liver transplant patients.

Edratide® CDR1-based peptide derived from a human anti-DNA antibody. Currently in phase I clinical trials for systemic lupus erythematosus (SLE), licensed to Teva Pharmaceuticals Ltd.

Tookad® Pd-bacteriophephorbide photosensitizer (WST09) is a novel light-responsive drug, based on chlorophyll that has been shown to kill tumor tissues by destroying their blood supply after local illumination with a diode laser (763 nm). It then rapidly clears from the body. Licensed to Steba Biotech. Currently in phase I/II clinical trials as second line therapy for prostate cancer patients who had had failed radiation therapy.

XTL-6865® Combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein. It is being developed to prevent hepatitis C, known as HCV, re-infection following a liver transplant and for the treatment of chronic HCV. Licensed to XTL Biopharmaceuticals Ltd. (XTLbio). Currently in phase Ia/Ib clinical trials.

Tadekinig-α® Recombinant IL-18 binding protein (r-IL-18 BP), currently in phase I clinical trials for Crohn’s disease and rheumatoid arthritis, licensed to Serono

Yeda has also participated in the establishment of a large number of companies for development of institute discoveries, with seven new companies established since 2004.

Yeda – Johnson & Johnson Joint fund

In December 2005, Johnson & Johnson (J&J) and Yeda launched a new joint fund.

This joint fund, to which J&J and Yeda have made equal contributions, was initiated to facilitate scientific crosstalk and to expose the excellent science of Weizmann researchers to J&J. We encourage you to submit research proposals for funding consideration.

The fund will support life science projects in the fields of pharmaceuticals, diagnostics and medical devices, at around 60K$ (including WIS overhead) annually. More details about this fund can be found in the Request for Proposals (link available only to Weizmann personnel).

Seeking Additional Partners

We are actively seeking additional commercial partners and entrepreneurs that can help us to bring Weizmann Institute’s technologies to the marketplace.

To search Yeda’s licensing and investment opportunities, please go to Opportunity Search.

We are interested in receiving your requests, feedback or comments. Please don’t hesitate to Contact Yeda.

Additional information on the business opportunities offered by Yeda, can be found at:

http://yeda.weizmann.ac.il